Kodiak Sciences (KOD) Price & Analysis

Compare

431 Followers

KOD Stock Chart & Stats

$24.30

-$0.42(-4.39%)

At close: Jan 08 4:00 PM EST

$24.30

-$0.42(-4.39%)

Day’s Range― - ―

52-Week Range$1.92 - $31.18

Previous CloseN/A

Volume87.32K

Average Volume (3M)756.04K

Market Cap

$1.41B

Enterprise Value$1.28B

Total Cash (Recent Filing)$72.04M

Total Debt (Recent Filing)$62.20M

Price to Earnings (P/E)―

Beta2.87

Next Earnings

Mar 26, 2026

EPS Estimate

-1.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.16

Shares Outstanding61,048,428

10 Day Avg. Volume704,946

30 Day Avg. Volume756,044

Financial Highlights & Ratios

PEG Ratio0.09

Price to Book (P/B)3.48

Price to Sales (P/S)0.00

P/FCF Ratio-4.44

Enterprise Value/Market Cap0.91

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-48.19

Enterprise Value/Ebitda-6.69

Forecast

1Y Price Target

$31.80

Price Target Upside30.86% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering6

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Analyst ConvictionAnalyst reiteration of a Buy rating and higher conviction ahead of pivotal readouts signals increased market confidence that positive trial outcomes could materially boost the ABC platform and share sentiment.

KSI-101 Clinical PerformanceFinal Phase 1B APEX data showing meaningful anatomical and visual improvements with KSI-101 support the IL-6/VEGF bispecific approach as a potential best-in-class option for retinal disease, enhancing program credibility.

Pivotal Clinical ReadoutsPivotal Phase 3 readouts for reformulated tarcocimab and KSI-501 could validate improved immediacy and extended durability versus current anti-VEGF therapies, which may drive stronger adoption and upward stock re-rating if results are supportive.

Bears Say

Financing RiskA limited cash runway of roughly six months increases financing risk and could pressure the share price if pivotal readouts do not produce a strong positive investor response or additional funding is delayed.

Legacy Safety IssuesA prior formulation was associated with increased cataract rates that confounded visual outcomes and contributed to late-stage trial failures, keeping safety concerns top of mind for investors evaluating the reformulated program.

Reformulation Efficacy UncertaintyOutstanding questions remain whether the antibody–biopolymer conjugate reformulation will deliver meaningful efficacy gains after earlier Phase 3 setbacks, which raises execution and clinical risk for the programs.

Kodiak Sciences News

Kodiak Sciences price target raised to $38 from $26 at H.C. Wainwright

H.C. Wainwright analyst Matthew Caufield raised the firm’s price target on Kodiak Sciences (KOD) to $38 from $26...

20d ago

KOD

Kodiak Sciences: GLOW2 Readout as Key Catalyst for Tarcocimab Upside and Broader Pipeline Optionality

J.P. Morgan analyst Anupam Rama has maintained their bullish stance on KOD stock, giving a Buy rating on...

9d ago

KOD

Aligos Therapeutics initiated with a Buy at UBS

UBS analyst Michael Yee initiated coverage of Aligos Therapeutics (ALGS) with a Buy rating and $20 price target...

1M ago

IVA

KOD

Kodiak Sciences assumed with a Buy at UBS

UBS assumed coverage of Kodiak Sciences (KOD) with a Buy rating and $50 price target as the analyst...

1M ago

KOD

Kodiak Sciences Raises Capital Through Completed Stock Offering

The latest announcement is out from Kodiak Sciences ( ($KOD) ). On December 16, 2025, Kodiak Sciences Inc....

2M ago

KOD

Kodiak Sciences 6.956M share Spot Secondary priced at $23.00

The deal size was increased to 6.956M shares of common stock from 6M shares of common stock. JPMorgan,...

2M ago

KOD

Closing Bell Movers: Ford nudges higher raised outlook, EV charge

U.S. indices followed Friday’s broad selloff with more malaise on Monday, led by weakness in Technology and Energy...

2M ago

Kodiak Sciences announces 6M share offering of common stock

Kodiak Sciences (KOD) announced that it has commenced an underwritten public offering of 6M of shares of its...

2M ago

KOD

Kodiak Sciences’ Promising Outlook: Buy Rating Affirmed Amid Positive Drug Developments and Strategic Adjustments

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on Kodiak Sciences today and set a price target...

3M ago

KOD

Kodiak Sciences price target raised to $26 from $24 at H.C. Wainwright

H.C. Wainwright analyst Matthew Caufield raised the firm’s price target on Kodiak Sciences (KOD) to $26 from $24...

3M ago

KOD

Kodiak Sciences: Promising Pipeline and Strategic Differentiation Drive Buy Rating

Kodiak Sciences, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Dolezal from...

3M ago

KOD

Kodiak Sciences Faces Financial Challenges Amid R&D Focus

Kodiak Sciences ( ($KOD) ) has released its Q3 earnings. Here is a breakdown of the information Kodiak...

3M ago

KOD

Kodiak Sciences reports Q3 EPS ($1.16), consensus ($1.04)

“Kodiak Sciences (KOD) has entered a period of strong, sustained momentum driven by compelling clinical data, accelerated execution...

3M ago

KOD

Kodiak Sciences upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright analyst Matthew Caufield upgraded Kodiak Sciences (KOD) to Buy from Neutral with a price target of...

3M ago

KOD

KOD FAQ

What was Kodiak Sciences Inc’s price range in the past 12 months?

Kodiak Sciences Inc lowest stock price was $1.92 and its highest was $31.18 in the past 12 months.

What is Kodiak Sciences Inc’s market cap?

Kodiak Sciences Inc’s market cap is $1.41B.

When is Kodiak Sciences Inc’s upcoming earnings report date?

Kodiak Sciences Inc’s upcoming earnings report date is Mar 26, 2026 which is in 43 days.

How were Kodiak Sciences Inc’s earnings last quarter?

Kodiak Sciences Inc released its earnings results on Nov 13, 2025. The company reported -$1.16 earnings per share for the quarter, missing the consensus estimate of -$1.037 by -$0.123.

Is Kodiak Sciences Inc overvalued?

According to Wall Street analysts Kodiak Sciences Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kodiak Sciences Inc pay dividends?

Kodiak Sciences Inc does not currently pay dividends.

What is Kodiak Sciences Inc’s EPS estimate?

Kodiak Sciences Inc’s EPS estimate is -1.01.

How many shares outstanding does Kodiak Sciences Inc have?

Kodiak Sciences Inc has 61,048,428 shares outstanding.

What happened to Kodiak Sciences Inc’s price movement after its last earnings report?

Kodiak Sciences Inc reported an EPS of -$1.16 in its last earnings report, missing expectations of -$1.037. Following the earnings report the stock price went up 3.392%.

Which hedge fund is a major shareholder of Kodiak Sciences Inc?

Currently, no hedge funds are holding shares in KOD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Kodiak Sciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

-207.92%

Trailing 12-Months

Asset Growth

-41.48%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Kodiak Sciences Inc

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Kodiak Sciences (KOD) Earnings & Revenues

Historic Earnings Reports

KOD Stock 12 Month Forecast

Average Price Target

$31.80

▲(30.86% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","26":"$26","51":"$51","13.5":"$13.5","38.5":"$38.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$31.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,13.5,26,38.5,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.11,26.10153846153846,28.09307692307692,30.084615384615383,32.076153846153844,34.067692307692305,36.059230769230766,38.050769230769234,40.04230769230769,42.033846153846156,44.02538461538461,46.01692307692308,48.00846153846154,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.11,24.701538461538462,25.293076923076924,25.884615384615383,26.476153846153846,27.067692307692308,27.65923076923077,28.25076923076923,28.842307692307692,29.433846153846154,30.025384615384617,30.61692307692308,31.208461538461542,{"y":31.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.11,23.33230769230769,22.554615384615385,21.776923076923076,20.99923076923077,20.22153846153846,19.443846153846152,18.666153846153847,17.888461538461538,17.11076923076923,16.333076923076923,15.555384615384614,14.777692307692307,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.43,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.95,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.11,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.56,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.49,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.76,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.65,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.62,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":15.76,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":18.12,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.94,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.96,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.11,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >